ADAM12 AS A BIOMARKER FOR BLADDER CANCER

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20090029372A1
SERIAL NO

12120544

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present inventors have shown that the gene and protein expression profiles of ADAM8, ADAM10 and ADAM12 in different grades and stages of bladder cancer.ADAM12 gene expression was evaluated in tumors from 96 patients with bladder cancer using a customized Affymetrix GeneChip. Gene expression in bladder cancer was validated using reverse transcription-polymerase chain reaction (RT-PCR), quantitative PCR, and in situ hybridization. Protein expression was evaluated by immunohistochemical staining on tissue arrays of bladder cancers.The presence and relative amount of ADAM12 in the urine of cancer patients were determined by Western blotting and densitometric measurements, respectively.Particularly ADAM12 mRNA expression was significantly upregulated in bladder cancer, as determined by microarray analysis, and the level of ADAM12 mRNA correlated with disease stage. ADAM12 protein expression correlated with tumor stage and grade. ADAM12 was present in higher levels in the urine from bladder cancer patients than in urine from healthy individuals. Significantly, following removal of tumor by surgery, in most bladder cancer cases examined the level of ADAM12 in the urine decreased and, upon recurrence of tumor, increased.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
PHYSICIANS CHOICE LABORATORY SERVICES LLC854 PARAGON WAY ROCK HILL SC 29730

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Wewer, Ulla M Klampenborg, DK 6 75

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation